Disturbing mitochondrial functionalities on the utilization of Lenvatinib-conjugated Gallium (III) nanocomposites as therapeutic avenue to potentiate hepatocellular carcinoma inhibition
Journal of Pharmaceutical Analysis · 2026-10 · 16 (10) · 101736
DOI: 10.1016/j.jpha.2026.101736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-10. Verfasst von Mengyao Dai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Ch…. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
- Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Förderung
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Dai, M., Chen, Q., Song, J., Ma, X., Ma, K., Wei, X., Niu, Y., Liang, T., Zhang, Q., Li, Y., & Fu, Q. (2026). Disturbing mitochondrial functionalities on the utilization of Lenvatinib-conjugated Gallium (III) nanocomposites as therapeutic avenue to potentiate hepatocellular carcinoma inhibition. Journal of Pharmaceutical Analysis, 16(10), 101736. https://doi.org/10.1016/j.jpha.2026.101736
Vancouver
Dai M, Chen Q, Song J, Ma X, Ma K, Wei X, et al. Disturbing mitochondrial functionalities on the utilization of Lenvatinib-conjugated Gallium (III) nanocomposites as therapeutic avenue to potentiate hepatocellular carcinoma inhibition. Journal of Pharmaceutical Analysis. 2026;16(10):101736. doi:10.1016/j.jpha.2026.101736
BibTeX
@article{Dai2026,
author = {Dai, Mengyao and Chen, Qitai and Song, Jinyuan and Ma, Xinpeng and Ma, Ke and Wei, Xiaobao and Niu, Yumiao and Liang, Tingbo and Zhang, Qi and Li, Yangyang and Fu, Qihan},
title = {Disturbing mitochondrial functionalities on the utilization of Lenvatinib-conjugated Gallium (III) nanocomposites as therapeutic avenue to potentiate hepatocellular carcinoma inhibition},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
volume = {16},
number = {10},
pages = {101736},
doi = {10.1016/j.jpha.2026.101736}
}
EUVIMED